Over my 20 years practicing medicine, I have seen many changes in how we care for patients. Change is not only expected in medicine — it is essential.
As new evidence emerges from research, observation and clinical experience, recommendations evolve. This evidence-based process is how vaccines, including the hepatitis B (HBV) vaccine, have been developed and refined over decades to demonstrate both safety and effectiveness.
For this reason, the Advisory Committee on Immunization Practices’ (ACIP) Dec. 5 decision to move away from a longstanding recommendation for a universal birth dose of the hepatitis B vaccine raised significant concern among medical providers and public health officials.
The change was not supported by new data or studies, despite more than 40 years of research and 35 years of post-marketing surveillance supporting both the safety and benefit of administering the vaccine within 24 hours of birth.
HBV infection in infancy carries serious consequences. Approximately 90% of infants infected with HBV develop chronic infection, which is not curable, and about 25% of those individuals will eventually die from cirrhosis or liver cancer. These risks are far higher in infants than in older children, adolescents or adults, most of whom clear the infection naturally, which is why prevention starting at birth is so critical.
The updated ACIP recommendation emphasizes “individual-based decision making,” suggesting vaccination based on maternal testing rather than universal administration.
However, shared decision-making between parents and clinicians has always been part of pediatric care, and parents have long retained the ability to consent to or decline vaccines. The concern is not encouraging shared decision making itself, but that de-emphasizing the importance of the birth dose undermines confidence of parents in giving it when it is most critical or even at all in many people’s minds.
A strategy focused solely on identifying and vaccinating infants born to HBV-positive mothers has been tried before and was found to not significantly lower infection rates across the whole population. Not all pregnant individuals receive prenatal care or HBV testing, infection can be acquired later in pregnancy after testing, and roughly half of pediatric HBV infections are not transmitted by the mother.
HBV is highly contagious, often asymptomatic for years, and can survive on surfaces for at least seven days, making transmission even via small breaks in the skin common when exposed to an unrecognized contaminated surface.
Historically, the U.S. initially targeted vaccination to high-risk groups beginning in the early 1980s. After a decade with little reduction in HBV incidence, recommendations shifted in 1991 to universal infant vaccination. Since then, pediatric HBV infections have declined dramatically — from an estimated 18,000-32,000 cases annually to just 250 reported cases in 2022 — representing nearly a 99% reduction. This decline has prevented tens of thousands of future cases of cirrhosis and liver cancer.
Waiting increases the chances of contracting a virus they may never clear and will shorten their lives.
The hepatitis B vaccine has an extensive safety record. Serious adverse events are extremely rare, with anaphylaxis occurring in approximately one per million doses, and no associated deaths reported. It’s made even safer when the first dose is given while monitored in the hospital just after birth. Weighing the benefits and harms, it’s clearly safer to get the vaccine than risk contracting hepatitis B infection.
Given this longstanding evidence, pediatric and medical organizations and state health departments continue to support universal hepatitis B vaccination beginning at birth. While thoughtful discussion with families is always appropriate, decades of data suggest that early, universal protection remains the most reliable way to prevent a life-threatening infection in children.
Dr. Mindy Frimodig is a family physician at ThedaCare Medical Center-Shawano and a member of the Shawano Community Health Action Team.
